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Abstract
Background:  The induction of antigen-specific CD8+ T cell cytokine responses against an
attenuated, oral recombinant Salmonella enterica serovar Typhimurium vaccine expressing a green
fluorescent protein (GFP) model antigen was investigated. A GFP expression plasmid was
constructed in which the gfp gene was fused in-frame with the 5' domain of the Escherichia coli β-
galactosidase α-gene fragment with expression under the lac promoter. Groups of mice were orally
immunized three times with the bacteria and systemic CD8+ T cell cytokine responses were
evaluated.
Results: High level of the GFP model antigen was expressed by the recombinant Salmonella vaccine
vector. Systemic GFP-specific CD8+ T cell cytokine (IFN-γ and IL-4) immune responses were
detected after mice were orally vaccinated with the bacteria. It was shown that 226 net IFN-γ and
132 net IL-4 GFP-specific SFUs/10e6 splenocytes were formed in an ELISPOT assay. The level of
IFN-γ produced by GFP peptide-stimulated cells was 65.2-fold above background (p < 0.05). The
level of IL-4 produced by the cells was 10.4-fold above background (p < 0.05).
Conclusion: These results suggested that a high expressing recombinant Salmonella vaccine given
orally to mice would elicit antigen-specific CD8+ T cell responses in the spleen. Salmonella bacteria
may, therefore, be used as potential mucosal vaccine vectors.
Background
Most Salmonella  bacteria invade their hosts (human or
animal) via the mucosal route to cause systemic infection
[1]. They are taken up by phagocytes and they stay in the
phagosomes of these cells. Antigens from Salmonella are
mainly targeted to the MHC class II presentation pathway
for induction of CD4+ T cell immune responses. How-
ever, both CD4+ and CD8+ T lymphocytes are crucial for
protective immune responses against intracellular patho-
gens such as Salmonella [2-4]. In recent years, attenuated
strains of Salmonella  have been explored as potential
mucosal vaccine vectors for heterologous antigens [5-11].
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One of the main advantages of using Salmonella as vaccine
vectors is their ability to induce both mucosal and sys-
temic immune responses to the foreign antigens. In order
to investigate the induction of antigen-specific CD8+ T
cell responses to a foreign antigen, we developed a recom-
binant Salmonella vector expressing jellyfish Aequorea vic-
toria green fluorescent protein (GFP) as a model antigen.
The GFP model antigen contains a mouse H-2Kd-
restricted class I epitope, HYLSTQSAL, identified previ-
ously by Gambotto and co-workers [12] and can be used
to evaluate CD8+ T cell responses after vaccinations. We
then investigated the potential of using a Salmonella vac-
cine in delivering the GFP CD8+ epitope to the immune
system. The study was done against a backdrop for the
need to develop vaccines that induce CD8+ T cell
responses in the mucosal and systemic compartments in
which Salmonella may be used as a mucosal vector admin-
istered orally. In order to understand the steps required
for the development of such vaccines, we therefore con-
structed the recombinant Salmonella enterica serovar Typh-
imurium expressing GFP as a model foreign antigen and
tested its systemic immune responses in mice after oral
vaccination by gavage.
Results
A recombinant Salmonella vaccine vector was constructed
A prokaryotic expression cassette was developed in which
the gfp gene was fused in-frame with an E coli β-galactosi-
dase α-fragment sequence (N-terminus) (Figure 1). The
gfp gene was amplified and cloned into pGEM-Teasy plas-
mid vector. The β-galactosidase  α-fragment with DNA
sequence (5'-ATG ACC ATG ATT ACG CCA AGC TAT TTA
GGT GAC ACT ATA GAA TAC TCA AGC TAT GCA TCC
AAC GCG TTG GGA GCT CTC CCA TAT GGT CGA CCT
GCA GGC GGC CGC GAA TTC ACT AGT GAT-3') had 24
amino acids (MTMITPSYLG DTIEYSSYAS NALGALPYGR
PAGGREFTSD) and the peptide was 4.2 kDa in size. A
small linker (L) sequence with 15 codons (5-TAT GGC
GCC AAA GAC TCC GGC TCC GCC GGT TCC GCC GGC
TCA GCT-3) was incorporated between the β-galactosi-
dase α-fragment and gfp. The linker peptide had 15 amino
acids (YGAKDSGSAG SAGSA) and a molecular weight of
1.266 kDa. The gfp  gene had 237 amino acids
(SKGEELFTGV VPILVELDGD VNGHKFSVSG EGEG-
DATYGK LTLKFICTTG KLPVPWPTLV TTFSYGVQCF
SRYPDHMKRH DFFKSAMPEG YVQERTISFK
DDGNYKTRAE VKFEGDTLVN RIELKGIDFK EDG-
NILGHKL EYNYNSHNVY ITADKQKNGI KANFKIRHNI
EDGSVQLADH YQQNTPIGDG PVLLPDNHYL STQSAL-
SKDP NEKRDHMVLL EFVTAAGITH GMDELYK) and a
molecular weight of 26.6 kDa. The GFP contains a Balb/C
mouse CD8+ T cell epitope, HYLSTQSAL. The whole β-
galactosidase-GFP fusion protein was 32.1 kDa. A pre-
ferred translation stop codon (TAAG) which was incorpo-
rated in the PCR primer, GR, was found at the end of the
gfp gene. There was also an extra stop codon, TAAT, one
codon downstream the end of the gfp gene.
Very high level constitutive expression of GFP antigen by
the recombinant Salmonella enterica serovar Typhimu-
rium, AroC+GFP, was demonstrated (Figure 2). Colonies
and cultures of the bacterial vaccine, AroC+GFP, fluo-
resced brightly green under UV light. SDS-PAGE analysis
showed that GFP antigen was the most highly expressed
antigen by the Salmonella vaccine vector (Figure 2A). The
GFP protein band was visible on the Coomassie-stained
gel. Western blotting further confirmed that GFP antigen
was expressed at very high levels by the vaccine vector
(Figure 2B). There was no expression of GFP by the nega-
tive control vaccine, AroC+pGEM.
Oral vaccination induces IFN-γ and IL-4 cytokine 
producing CD8+ splenocytes
The induction of GFP-specific CD8+ T cells in the spleen
was evaluated on Day 84 after oral vaccination of mice
with a dose of 10e8 colony-forming units either with
AroC+GFP or the control (AroC+GEM) on Days 0, 28 and
56. Both IFN-γ and IL-4 producing GFP-specific CD8+ T
cells were evaluated after sacrifice of mice. A high magni-
tude of GFP-specific CD8+ T cells was detected when the
The GFP expression plasmid (pGEM+GFP) Figure 1
The GFP expression plasmid (pGEM+GFP). The gfp 
was fused in-frame to the β-galactosidase α-gene in pGEM-
Teasy plasmid. A small linker (L) was included (in-frame) 
between the gfp and β-galactosidase α-gene (lacZa). E. coli lac 
(lactose) promoter was upstream the genes. A start codon 
was in the β-galactosidase α-gene and a stop codon was 
included at the end of the gfp gene. The expression cassette 
contained an E. coli origin of replication (ori) and ampicillin 
resistance gene (AmpR).
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GFP peptide was included in the IFN-γ and IL-4 ELISPOT
assays (Tables 1 and 2). The number of cells secreting IFN-
γ after stimulation with a GFP CD8 peptide were signifi-
cantly higher in AroC+GFP than in the negative control
vaccine, AroC+pGEM (p < 0.05) (Table 1). There was no
significant difference in response between the two groups
when the cells were stimulated with media or full-length
GFP (p > 0.05). Response to the LPS stimulation differed
between the two groups (p < 0.05). Analysis of the
responses within the AroC+GFP group showed that the
number of cells producing IFN-γ were significantly higher
when stimulated with GFP CD8 peptide than when not
stimulated (p < 0.05) (Table 1). In the negative vaccine
group, AroC+pGEM, there was no difference in response
in GFP peptide-stimulated cells and unstimulated cells (p
> 0.05) (Table 1).
The number of cells from AroC+GFP vaccine group pro-
ducing IL-4 were also significantly higher than in
AroC+pGEM after stimulation with GFP CD8 peptide (p <
0.05) (Table 2). However no significant difference in
response between the two groups were observed when the
cells were stimulated with media, full-length GFP or Sal-
monella LPS (p > 0.05). Within the AroC+GFP group, the
number of cells producing IL-4 were significantly higher
when stimulated with GFP CD8 peptide than when
unstimulated (p < 0.05) (Table 2). No difference in IL-4
responses was observed within the AroC+pGEM group
between GFP peptide-stimulated and unstimulated cells
(p > 0.05) (Table 2).
The cytometric bead array (CBA) assay and flow cytometry
analysis were used to quantify the IFN-γ and IL-4 simulta-
neously produced by splenocytes after stimulation with
the GFP H-2Kd binding peptide (HYLSTQSAL). Cells from
AroC+GFP produced higher levels of IFN-γ when stimu-
lated with the GFP CD8 peptide than when unstimulated
(p < 0.05) (Figure 3). The IFN-γ cytokine levels were also
higher in the test group (AroC+GFP) than in the negative
vaccine group (AroC+pGEM) (p < 0.05) (Figure 3). There
was no difference in the amount of IFN-γ produced
between stimulated and unstimulated cells within the
negative control vaccine (p > 0.05) (Figure 3). As with
IFN-γ, the same trends were observed with IL-4 (Figure 4).
Cells from AroC+GFP produced higher levels of IL-4 when
stimulated with GFP peptide than when unstimulated (p
< 0.05). The level of the IL-4 produced by the stimulated
cells was 10.4-fold above background. GFP peptide-stim-
ulated cells from AroC+GFP also produced significantly
higher levels of IL-4 than cells from the negative control
GFP expression by the Salmonella vaccine vector Figure 2
GFP expression by the Salmonella vaccine vector. Recombinant Salmonella expressing GFP (AroC+GFP) or Salmonella 
carrying an empty plasmid (AroC+pGEM) were grown overnight. GFP expression by the bacteria was determined by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (A) and confirmed by Western Blotting (B).
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vaccine, AroC+pGEM (p < 0.05). The results from CBA
further confirmed the ELISPOT results which showed that
a significant number of cells produced both IFN-γ and IL-
4 after stimulation with the GFP CD8 peptide. Further
analysis of the both ELISPOT and CBA assay results
showed that GFP-specific IFN-γ was produced at a rate of
2.56 pg/cell as opposed to GFP-specific IL-4 which was
produced at 1.63 pg/cell.
Discussion
Attenuated Salmonella bacteria have the potential of being
used as vaccine vectors for foreign antigens (5–11). One
of the key challenges with these vaccine delivery systems
is to optimize the expression of high levels of the foreign
antigens for successful delivery to the immune system. In
the current study, a strategy based on E. coli lac operon
control sequences was employed and tested for expression
of a model foreign antigen, Aequorea victoria green fluores-
cent protein, in aroC Salmonella enterica serovar Typhimu-
rium vaccine mutant. The E. coli lac promoter was used
and the gfp gene was successfully fused in-frame with first
40 codons of the E coli β-galactosidase α-fragment. The
inclusion of the N-terminal domain of the β-galactosidase
α-gene fragment, which itself is an E. coli bacterial peptide
potentially contributed to the high-level expression of
GFP observed in the Salmonella enterica serovar Typhimu-
rium vector. Fusing foreign proteins to other prokaryotic
peptides has the potential of enhancing the expression of
the cloned genes [13]. Furthermore, fusion proteins have
been shown to be, in most cases, resistant to proteolytic
Table 1: The magnitude of GFP-specific CD8+ T cell responses as measured by IFN-γ ELISPOT assay
Stimulant IFN-γ SFUs/10e6 cells p-value
AroC+GFP Group AroC+pGEM Group
Media 6 ± 2 7 ± 5 0.84
GFP CD8 peptide 232 ± 15 6 ± 2 0.0001
GFP protein 4 ± 0 4 ± 2 1.00
Salmonella LPS 244 ± 39 375 ± 62 0.037
Vaccine group Media GFP peptide p-value
AroC+GFP 6 ± 2 233 ± 15 0.0001
AroC+pGEM 7 ± 5 6 ± 2 0.70
Groups of mice were vaccinated three times (Days 0, 28 and 56) with live recombinant Salmonella vaccine expressing GFP (AroC+GFP) or a 
negative Salmonella control vaccine not expressing any antigen (AroC+pGEM). On Day 84 (28 days after the last inoculation), splenocytes from the 
sacrificed mice were incubated with media only (negative assay control), or stimulated with GFP CD8+ T cell peptide (HYLSTQSAL), full-length 
GFP or Salmonella LPS in an IFN-γ ELISPOT assay. The mean number of spots ± SD in triplicate wells was calculated and expressed as IFN-γ SFUs/
10e6 cells. Difference in response between or within vaccines was determined. Responses differ significantly if the p-values are less than 0.05 and do 
not differ significantly if the p-values are greater than 0.05.
Table 2: The magnitude of GFP-specific CD8+ T cell responses as measured by IL-4 ELISPOT assay
Stimulant IL-4 SFUs/10e6 cells p-value
AroC+GFP Group AroC+pGEM Group
Media 16 ± 10 12 ± 2 0.55
GFP CD8 peptide 148 ± 56 12 ± 13 0.015
GFP protein 18 ± 13 29 ± 26 0.56
Salmonella LPS 55 ± 29 26 ± 9 0.17
Vaccine group Media GFP peptide p-value
AroC+GFP 16 ± 10 148 ± 56 0.016
AroC+pGEM 12 ± 2 12 ± 13 0.97
Groups of mice were vaccinated three times (Days 0, 28 and 56) with live recombinant Salmonella vaccine expressing GFP (AroC+GFP) or a 
negative Salmonella control vaccine not expressing any antigen (AroC+pGEM). On Day 84 (28 days after the last inoculation), splenocytes from the 
sacrificed mice were incubated with media only (negative assay control), or stimulated with GFP CD8+ T cell peptide (HYLSTQSAL), full-length 
GFP or Salmonella LPS in an IL-4 ELISPOT assay. The mean number of spots ± SD in triplicate wells was calculated and expressed as IL-4 SFUs/10e6 
cells. Difference in response between or within vaccines was determined. Responses differ significantly if the p-values are less than 0.05 and do not 
differ significantly if the p-values are greater than 0.05.Gut Pathogens 2009, 1:9 http://www.gutpathogens.com/content/1/1/9
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degradation, thereby overcoming the problems of insta-
bility normally associated with foreign proteins [14,15].
The fusion of gfp to the 5'-domain of LacZα also poten-
tially stabilized GFP mRNA of the antigen gene and
increased its half-life. In a similar study, it was shown that
fusing genes to the 5' UTR (untranslated region) of ompA
was effective in stabilizing the mRNA transcripts [16].
Other considerations that potentially contributed to the
high level expression of GFP antigen were the nature of
the ribosome-binding site, the origin of replication (ori),
promoter (lac) properties, and translation termination
sequences. These transcriptional and translational
domains are present in the pGEM-Teasy plasmid
(Promega, USA). The origin of replication of the pGEM-
Teasy plasmid allowed for high copy number of the plas-
mid (300–400 copies per cell) in Salmonella  vector,
thereby increasing the gfp gene dosage and high expres-
sion of the antigen. The natural Shine Dalgarno sequence
(ribosome binding site) for the LacZα gene in the pGEM-
Teasy plasmid was used for efficient bacterial ribosome
binding. The stop codon, TAA(G) was used in the
pGEM+GFP plasmid to increase efficiency of translation
termination. The high-level GFP expression was antici-
pated to facilitate the delivery of sufficient antigen to the
immune system by the Salmonella vector after vaccination.
Development of bacterial vaccine vectors that provoke
antigen-specific CD8+ T cell responses in the mucosal and
systemic compartments is a key challenge. In this study,
we were able to demonstrate that oral vaccination of mice
with a recombinant aroC Salmonella enterica serovar Typh-
imurium mutant overexpressing a heterologous model
antigen could induce antigen-specific CD8+ T cell
cytokine immune responses in the spleen. Using the ELIS-
POT assay, it was shown that after three oral immuniza-
tions of mice with AroC+GFP, there was production of
both antigen-specific IFN-γ and IL-4 cytokine secreting
CD8+ cells in the spleen. The ELISPOT results were further
confirmed by the CBA assay which showed that high lev-
els of IFN-γ and IL-4 cytokines could be secreted by the
splenocytes when stimulated with a GFP CD8 peptide.
The induction of LPS-specific IFN-γ and IL-4 suggested
The magnitude of GFP-specific CD8+ T cell responses as determined by quantification of IFN-γ cytokine Figure 3
The magnitude of GFP-specific CD8+ T cell responses as determined by quantification of IFN-γ cytokine. 
Groups of mice were vaccinated three times (Days 0, 28 and 56) with live recombinant Salmonella vaccine expressing GFP 
(AroC+GFP) or a negative Salmonella control vaccine not expressing any antigen (AroC+pGEM). On Day 84 (28 days after the 
last inoculation), splenocytes from the sacrificed mice were incubated with media only (negative assay control) or stimulated 
with GFP CD8+ T cell peptide (HYLSTQSAL), and the amounts of IFN-γ measured by CBA assay. Each bar in the graphs rep-
resents the average picogram amount of cytokine produced per 10e6 splenocytes in 48 hrs of stimulation. One asterisk indi-
cates values that differ significantly (p < 0.05). Two asterisks indicate values that do not differ significantly (p > 0.05).
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that the bacterial vaccine was delivered successfully to the
immune system.
Salmonella antigens or heterologous antigens expressed by
Salmonella vaccine vectors are expected to be presented
mainly by the MHC-II molecules to give predominantly
antigen-specific CD4+ T cell responses. This is mainly
because Salmonella bacteria always dwell in the phago-
somes and antigens are presented to the immune system
by the MHC Class II pathway. The mechanisms by which
Salmonella-expressed antigens are presented to the
immune system by the MHC Class I pathway to induce
CD8+ T cell responses is still poorly understood. How-
ever, it is known that Salmonella have a high tropism for
dendritic cells and these cells have the capacity of cross-
priming exogenous antigens for induction of CD8+ T cell
responses [17-22]. Dendritic cells can also engulf the Sal-
monella-infected apoptotic cells which may be a key source
of antigens that can be processed for induction of CD8+ T
cell responses [17,18]. It seems that the high-level expres-
sion of the GFP shown in this study may have facilitated
antigen processing and cross-presentation for induction
of CD8+ T cell responses. The high amounts of the antigen
also potentially improved the immunodominance of GFP
CD8+ epitope over Salmonella vector epitopes. It has been
demonstrated that antigen abundance (antigen dose) is
one of the crucial factors that determine CD8+ T cell
immunodominance [23,24]. It was not clear whether IFN-
γ or IL-4 cytokines observed in this study were secreted by
the same or different CD8+ T cell populations as we did
not do flow cytometry to determine this. The ELISPOT
assays do not allow the characterization of the effector cell
populations secreting the two cytokines. However, the
data is only suggestive that IFN-γ was produced by type 1
CD8+ T (Tc1) cells while IL-4 was produced by type 2
CD8+ (Tc2) cells. The possible polarized pattern of
secreted cytokines by CD8+ T cells against the GFP model
antigen delivered by a Salmonella vaccine observed in the
current study might have a great relevance to immune
responses against many diseases. CD8+ Tc1 cells produce
cytokines such as IFN-γ and TNF-α that are critical in pre-
vention or control of infection. However, the immunolog-
ical and clinical significance of CD8+ Tc2 cells is still
poorly understood. Some reports suggest that that Tc2
cells provide B cell help by secretion of IL-4 and would
display cytotoxicity function just like the Tc1 cells [25-27].
The magnitude of GFP-specific CD8+ T cell responses as determined by quantification of IL-4 cytokine Figure 4
The magnitude of GFP-specific CD8+ T cell responses as determined by quantification of IL-4 cytokine. Groups 
of mice were vaccinated three times (Days 0, 28 and 56) with live recombinant Salmonella vaccine expressing GFP (AroC+GFP) 
or a negative Salmonella control vaccine not expressing any antigen (AroC+pGEM). On Day 84 (28 days after the last inocula-
tion), splenocytes from the sacrificed mice were incubated with media only (negative assay control) or stimulated with GFP 
CD8+ T cell peptide (HYLSTQSAL), and the amounts of IL-4 measured by CBA assay. Each bar in the graphs represents the 
average picogram amount of cytokine produced per 10e6 splenocytes in 48 hrs of stimulation. One asterisk indicates values 
that differ significantly (p < 0.05). Two asterisks indicate values that do not differ significantly (p > 0.05).
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Tc2 cells may also be correlated with better antibody
immune responses [28,29]. High numbers of CD8+ T
cells (Tc2) producing IL-4, but not IFN-γ, have been found
in AIDS patients [30]. It has also been established that Tc2
cells play a role in reducing metastasis of lung cancer [31].
Although a Salmonella vaccine vector eliciting foreign anti-
gen-specific IFN-γ may be useful, the impact of a vaccine
that induces antigen-specific IL-4 is poorly understood.
This study is unique in that we showed that expression of
a foreign antigen in the bacterial cytoplasmic space could
elicit antigen-specific cellular responses in vaccinated
mice. Other studies have only shown that CD8+ T cell
responses in mice could only be induced when antigens
were secreted from the bacteria or when prime-boost reg-
imens were used in the vaccination [33-36]. Unlike in
most studies, we also looked at the simultaneous induc-
tion of both IFN-γ and IL-4 cytokine responses elicited in
the systemic compartment of Salmonella-vaccinated mice.
Conclusion
In conclusion, we have shown that an oral recombinant
Salmonella mutant could be used as a vaccine vector that
could deliver a GFP model antigen for induction of sys-
temic antigen-specific CD8+ T cell cytokine (IFN-γ and IL-
4) responses. Using the current study as a model, future
investigations should further explore the possibility of
using attenuated oral recombinant bacteria as vaccine vec-
tors that induce specific CD8+ T cell responses. Such vac-
cine-induced immune responses are critical for
prevention or control of a number of pathogens such HIV.
Methods
Bacterial strains and culture conditions
Competent Escherichia coli SCS110 cells (Stratagene, USA)
were used in cloning and genetic manipulations. An aux-
otroph, ΔaroC Salmonella enterica serovar Typhimurium
mutant vaccine strain (TML-MD58) (Microscience Pty
Ltd, UK) was used as an attenuated vaccine for the expres-
sion of GFP. The strain has a deletion in the aroC gene,
which encodes chorismate synthase, an enzyme necessary
for the biosynthesis of aromatic compounds, tryptophan,
tyrosine, phenylalanine, para-aminobenzoic acid and 2,3-
dihydroxybenzoate [37]. The bacteria were grown in 2YT
media supplemented, where necessary, with ampicillin
and aromatic amino acids (tryptophan, tyrosine, phenyla-
lanine, para-aminobenzoic acid and 2,3-dihydroxyben-
zoate) as previously described [37,38].
Construction of a high-level GFP expression cassette
Unless stated otherwise, DNA manipulations were per-
formed using standard recombinant DNA methods [38].
A recombinant plasmid, designated pGEM+GFP, was con-
structed. The gfp  gene was amplified using GFP2 (for-
ward), 5'-ATG GCG CCA AAG ACT CCG GCT CCG-3' and
GR (reverse), 5'- AAG CTT ATT TGT ATA GTT CAT CCA
TGC-3') synthetic oligonucleotides as primers. The prim-
ers were rationally designed so that GR could have a pre-
ferred gram-negative bacterial stop codon, 5'-TAAG-3' at
its end and that after cloning of the gfp PCR product in
pGEM-Teasy (Promega, USA), there could be a second
stop codon, TAAT, one codon downstream of TAAG. The
primer GFP2 was designed so that the gfp  gene to be
amplified by polymerase chain reaction could be in-frame
with the 5' domain (first 40 codons) of β-galactosidase α-
gene in pGEM-Teasy vector. Restriction site for Nar I, 5'-
GGCGCC-3', was incorporated in the GFP2 primer. The
two primers had few base mismatches with their respec-
tive target DNA sequences in gfp template.
The polymerase chain reaction for amplification of gfp
was conducted in a 50 μl volume with 4.5 units AmpliTaq
Gold™ DNA polymerase (Applied Biosystems), 1× PCR
buffer, 1.5 μM of each primers (GFP2 and GR), 0.2 mM
deoxynucleotide triphosphates, 1.5 mM magnesium chlo-
ride and 10 ng of PEHAOGFP plasmid (provided by Dr W
Bourn, University of Cape Town). The PCR cycling condi-
tions were as follows: 1 cycle of 95°C for 5 min, 5 cycles
of 95°C for 45 s, 55°C for 30 s, 72°C for 2 min, 25 cycles
of 95°C for 45 s, 64°C for 30 s, 72°C for 2 min, and a
final extension of 72°C for 7 min. Analysis of the gfp
amplicon aliquot (5 μl) was done by agarose gel electro-
phoresis. An aliquot (1 μl) of remaining amplicon was
ligated into a linearized pGEM-Teasy (Promega, USA)
according to manufacturer's recommendations. The liga-
tion reaction was used in the genetic transformation of
competent  E. coli SCS110 cells using the heat-shock
method. The recombinant SCS110 clones harbouring the
recombinant plasmid (pGEM+GFP) were screened for
presence of gfp fragment and its orientation by blue-white
screening procedure and UV-illumination. The white and
fluorescing (candidate) clones were cultured using stand-
ard protocols. To investigate the presence of the recom-
binant  gfp  gene in plasmids, restriction mapping was
performed initially with EcoR1 followed by double diges-
tion with NarI and HindIII. The gfp gene in the candidate
pGEM+GFP plasmid was sequenced.
Preparation of ΔaroC Salmonella enterica serovar 
Typhimurium expressing GFP
To investigate the expression of recombinant GFP,
pGEM+GFP and pGEM (negative control) plasmids were
used in the genetic transformation of competent aroC Sal-
monella enterica serovar Typhimurium mutant by a stand-
ard heat-shock method [33]. The agar plates were
incubated overnight and fluorescence of colonies viewed
under UV light the following morning. Single colonies
were cultured in 100 ml 2 YT liquid broth with ampicillin
(100 μg/ml). To determine the expression of GFP by the
recombinant  Salmonella, total bacterial protein wasGut Pathogens 2009, 1:9 http://www.gutpathogens.com/content/1/1/9
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extracted from each culture, separated by a standard 12%
sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and visualized in the gel by
Coomassie blue staining. A standard Western blotting was
performed to identify and to confirm the specificity and
integrity of the GFP antigen band seen on the SDS-PAGE
after Coomassie blue staining. A mixture of two anti-GFP
mouse monoclonal antibodies (Clones 7.1 and 13.1)
(Roche Diagnostics) was used as a primary antibody
(diluted at 1.1000). Goat-anti-mouse immunoglobulins
conjugated to horseradish peroxidase (Biorad), diluted at
1.1000 were used as secondary antibody. The immunob-
lot was visualized by enhanced chemiluminescence
(Roche Diagnostics) and autoradiography according to
manufacturer's recommendations
Vaccination of mice and preparation of splenocytes
To prepare vaccine stocks, a single colony of recombinant
Salmonella  was inoculated into 200 ml of 2 YT liquid
media supplemented with ampicillin (100 ug/ml), and
aromatic amino acids (1×) and grown at 37°C with strong
aeration. The bacterial cells were harvested in the logarith-
mic phase (OD600 = 0.8–1.0) by centrifugation at 3000
rpm for 5 mins, washed once with equal volume of phos-
phate buffered saline (PBS, pH 7.4) and suspended in PBS
with 15% glycerol. The cultures were stored in aliquots at
-80°C until vaccination. The bacterial count in the vaccine
stocks was determined by plating of serial dilutions. The
vaccines were designated AroC+GFP (a recombinant aroC
Salmonella enterica serovar Typhimurium mutant express-
ing GFP) and AroC+pGEM (a recombinant control aroC
Salmonella enterica serovar Typhimurium harbouring an
empty plasmid, pGEM-Teasy).
All animal procedures were approved by the University of
Cape Town Animal Ethics Committee. Female H-2d BALB/
c mice (8–10 weeks old; and five per group) were pur-
chased from South Africa Vaccine Producers Pty Ltd
(Johannesburg, South Africa), housed at the University of
Cape Town Animal Unit and allowed to adapt for a mini-
mum of 10 days before vaccinations. Groups of female
BALB/c mice were inoculated by intragastric gavage with
10e8 colony forming units (CFUs)/mouse of either Salmo-
nella  vaccine (AroC+GFP) or negative control
(AroC+pGEM) on Days 0, 28 and 56. Mice were sacrifice
on Day 84 and spleens were pooled for each group. The
spleens were meshed using a rubber stopper and metal
grid (Sigma) placed in a petri dish to generate a single cell
suspension in RPMI 1640 medium (Invitrogen, USA). The
cell suspension was transferred to a 50 ml conical centri-
fuge tube. The volume was made up to 50 ml with RPMI
1640 medium. The cell suspension was centrifuged at
1500 rpm for 5 minutes to pellet the cells. The pellet was
re-suspended in 50 ml of RPMI 1640 medium and centri-
fuged as before. The pellet was then washed twice with 50
ml of RPMI 1640 medium. The cells were re-suspended in
50 ml R10 medium (RPMI 1640, 10% heat-inactivated
fetal calf serum, a mixture of pernicillin and streptomycin
(Invitrogen, USA), and 15 mM 2-mercaptoethanol
(Sigma, USA)). A single cell suspension of splenocytes
was prepared and red cells were lysed using erythrocyte
lysing buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM
Na2EDTA) for 1 min at room temperature. To count the
cells and determine viability, 1/10 dilution of the suspen-
sion was made in Trypan Blue and Neubauer counting
chamber used. Cell concentration in suspension was cal-
culated and adjusted to an appropriate concentration. For
use in ELISPOT assay, the splenocytes were adjusted to a
concentration of 5 × 10e6 cells per ml and 100 ul of this
stock was added to a single well which contained 100 ul
of the stimulant. For use in CBA assay, the splenocytes
were adjusted to a concentration of 15 × 10e6 cells per ml
and 100 ul of this stock was added to a single well which
contained 100 ul of the stimulant.
IFN-γ and IL-4 ELISPOT assays
The IFN-γ and IL-4 ELISPOT kits (BD Pharmingen) were
used according to manufacturer's recommendations.
Splenocytes were plated in triplicate at 0.5 × 10e6 cells/
well in a final volume of 200 μl of R10 medium (RPMI-
1640 with 10% heat-inactivated fetal calf serum, 15 mM
β-mercaptoethanol, 100 U penicillin per ml, and 100 μg
streptomycin) either alone or with stimulants at 4 μg/ml.
The stimulants used assays were media (no peptide), GFP
H-2Kd binding peptide (HYLSTQSAL), full-length GFP,
Salmonella lipopolysaccharide (LPS) (at a final concentra-
tion of 0.5 μg/ml). After incubation for 24 hrs (IFN-γ ELIS-
POT assay) or 48 hr (IL-4 ELISPOT assay), the plates were
processed to detect IFN-γ- or IL-4-spot-forming units
(SFUs) using Nova Red substrate (Vector Laboratories,
UK) according to the kit instructions. Spots were counted
using a CTL Analyzer (Cellular Technology, OH, USA)
and ImmunoSpot Version 3.2 software (Cellular Technol-
ogy OH, USA). The mean number of spots ± SD in tripli-
cate wells was calculated and expressed as SFUs/10e6
splenocytes. Differences in immune responses between
vaccine groups were analyzed by the two-sample t-test.
Cytometric Bead Array (CBA) assay
Splenocytes at a concentration of 1.5 × 10e6 per 200 ul
R10 culture medium (RPMI-1640 with 10% heat inacti-
vated fetal calf serum, 100 U penicillin per ml, and 100 μg
streptomycin) were cultured alone or with the individual
stimulants as in the ELISPOT assay. CD8+ Tc1 (IFN-γ) and
Tc2 (IL-4) cytokines secreted by the splenocytes were
quantified using a mouse Th1/Th2 cytokine cytometric
bead array (CBA) assay (BD Biosciences kit) and flow
cytometry analysis according to manufacturer's instruc-
tions. Results were expressed as pg cytokine per 1 × 10e6Gut Pathogens 2009, 1:9 http://www.gutpathogens.com/content/1/1/9
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splenocytes. Differences in immune responses between
vaccine groups were analyzed by the two-sample t-test.
List of abbreviations
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POT: Enzyme-linked immunospot; GFP: Green fluores-
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sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis; SFUs: Spot-forming units; 2YT: 2× Yeast Tryp-
tone.
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